ArticleAnatomy & cell biology2026
Low-intensity extracorporeal shock wave therapy ameliorates fibrosis and renal function in a preclinical model of chronic kidney disease.
Article in Anatomy & cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the potential therapeutic effects of low-intensity extracorporeal shock wave therapy (Li-ESWT) in the treatment of chronic kidney disease (CKD) using a preclinical mice model, which was established by high adenine diet. Four experimental groups were formed: normal (NL), NL+Li-ESWT (NL+ESWT), CKD, and CKD+Li-ESWT (CKD+ESWT), and received appropriate interventions over a period of 3 weeks. Immunohistochemistry analysis revealed significant upregulation of HSP70 expression, a marker for cells affected by mechanical stimulus, in the NL+ESWT group, confirming successful delivery of Li-ESWT to kidney tissues. Body weight, kidney weight, blood urea nitrogen (BUN), and creatinine values showed no significant differences between the NL and NL+ESWT groups, indicating that Li-ESWT alone did not affect these parameters. However, in the CKD+ESWT group, although kidney weight did not significantly differ from the CKD group, both body weight and renal function parameters showed marked improvement compared to the CKD group, suggesting a positive impact of Li-ESWT on general condition and renal function in CKD. The following histological examination showed that the CKD+ESWT group exhibited significantly reduced tubulointerstitial injury and fibrosis compared to the CKD group, further supporting the therapeutic potential of Li-ESWT in CKD management. To reveal potential modulation of ESWT on the upstream of fibrosis, fibrosis-related gene expressions,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.